Who founded Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals was founded by Brian P. Zambrowicz in 1995.

Who are Lexicon Pharmaceuticals's investors?

Lexicon Pharmaceuticals's investors include New Enterprise Associates (NEA).

How much funding has Lexicon Pharmaceuticals raised?

Lexicon Pharmaceuticals has disclosed $335.9M raised across 6 rounds.

Where is Lexicon Pharmaceuticals headquartered?

Lexicon Pharmaceuticals is headquartered in The Woodlands, US.

Lexicon Pharmaceuticals

NASDAQ: LXRX

The Woodlands, US · Founded 1995 · Delaware corporation · 280 employees on LinkedIn · 1 known investors

Find your way into Lexicon Pharmaceuticals

643 people in our graph share verified history with the Lexicon Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.

Cathy Friedmanunlockedknows Pablo Lapuerta · together at Harvard University (overlapped)

knows the team · via The University of Texas at Austin

knows the team · via Harvard University

×3knows the team · via Dartmouth College

knows the team · via Amarin

×2knows the team · via Seton Hall University

Lexicon Pharmaceuticals develops and commercializes pharmaceutical products, including the marketed drug INPEFA and drug candidates in clinical development such as sotagliflozin, pilavapadin, and LX9851, serving patients in need of treatments across various therapeutic areas.

Biotech

Founders & leadership

Lexicon Pharmaceuticals was founded in 1995 by Brian P. Zambrowicz.

Brian P. ZambrowiczinFounder · evp and csoformer

Brian T. CruminSenior Vice President and General Counsel

Rachel MartensinSVP, Partnerships and Corporate Strategy

Scott CoianteExecutive

Craig B. Granowitz inChief Medical OfficerCraig Granowitz is a physician with experience in pharmaceutical and biotech organizations, having held roles in sales, marketing, medical affairs, and corporate functions across multiple companies and the venture capital sector.

Wendy E. McDermottinSVP and Head of Human Resources

Lisa DeFrancesco inSVP, Investor Relations & Corporate CommunicationsLisa DeFrancesco is an executive officer at Lexicon Pharmaceuticals with nearly 25 years of experience in investor relations, communications, and corporate finance across healthcare, biotech, pharmaceuticals, and other industries.

Alan J. Main inExecutive Vice President, Innovation and Chemical SciencesAlan J. Main is an Executive Officer at Lexicon Pharmaceuticals with prior roles at Novartis and Ciba in large-cap pharmaceuticals, as well as experience at the biotech firms Coelacanth and Lexicon. He has worked across drug discovery, preclinical development, regulatory submissions, and commercial manufacturing, and led the development of marketed drugs XERMELO and INPEFA as well as pipeline candidates including pilavapadin and LX9851.

Pablo Lapuerta inExecutive Vice President and Chief Medical Officer2013–2020Pablo Lapuerta is an Executive Officer at Lexicon Pharmaceuticals, which develops and commercializes therapeutic products including marketed and clinical-stage pharmaceuticals. He brings experience across drug development, clinical operations, and commercial functions including sales, marketing, pricing, and reimbursement, with clinical expertise spanning cardiology, endocrinology, gastroenterology, and neuroscience.

Praveen TyleinExecutive

Jeffrey Wade inPresident | COO | CFO2021–2024Jeffrey Wade is an executive at Lexicon Pharmaceuticals who has led the company from inception through commercialization of pharmaceutical products, overseeing capital raises exceeding $1 billion, strategic partnerships, and the development of its marketed and pipeline assets.

Lonnel CoatsinChief Executive Officer & Director2014–2024

Investors · 1

New Enterprise Associates (NEA)Menlo Park · $200K – $40M

Reported raises · per SEC filings

Form D private placements

$335.9M disclosed across 6 rounds · 2014–2026

▶$55.7MraisedFeb 2026 · 1 investors · Pharmaceuticals

Rule 506(b)